简介：陈林义，曾任中国科学技术大学医院院长、眼科主任，现任合肥名人眼科医院院长。

简介：目的探讨眼球摘除或眼内容剜除羟基磷灰石义眼台植入术临床应用。方法眼内容剜除,后巩膜开窗,羟基磷灰石义眼台植入巩膜腔或肌锥内,分层紧密缝合巩膜、筋膜及结膜。结果2例2眼义眼台轻度外露,观察随访半年无发展,后行羊膜移植后愈合,其余21例21眼均无结膜裂开及义眼台外露,取得了满意的效果。结论眼内容剜除后一期植入义眼台于巩膜腔或肌锥内,术中充分降低巩膜、筋膜及结膜的张力,并紧密分层缝合是降低和预防结膜裂开,义眼台外露、脱出的关键。

简介：目的研究义眼座植入术后治疗上睑凹陷的手术方法及疗效,评估高密度聚乙烯及或羟基磷灰石复合人工骨眶内植入的安全性及有效性.方法应用眼眶三维影像检查和突眼计测量的方法,分析上睑凹陷发生的原因,测量义眼座植入术后眶内容及眼眶容积改变,以高密度聚乙烯或羟基磷灰石复合人工骨作为填充材料,对26例义眼座植入术后上睑凹陷的患者施行整复治疗,并进行比较研究.结果手术后2wk内,19例上睑凹陷病例术后均得到了明显的矫正,外观理想;5例残留轻度上睑凹陷;2例仍有中度上睑凹陷,经再填充后得到了矫正.随访6个月～4年,3例残留轻度上睑凹陷.复合人工骨眶内植入后随访6个月以上,无感染、排异及移位.结论对义眼座植入术后上睑凹陷的整复手术可获得满意疗效.高密度聚乙烯或羟基磷灰石复合人工骨眶内植入是安全及有效的.

简介：目的观察羟基磷灰石义眼座术后的临床疗效．方法行眼球内容物剜除术，剪断视神经，于4条直肌间剪开巩膜，一期植入羟基磷灰石义眼座于巩膜腔及肌锥内．结果随访6-24个月，12例均植入成功，无义眼座排斥，暴露，感染等并发症．获得满意的外观康复效果．结论羟基磷灰石义眼座是理想的眼眶内填充物，眼内容物剜除术后植入义眼座，明显改善术后眼窝塌陷畸形刑于义眼安装，无严重并发症，是一种眼眶美容术中的理想方法．

简介：病例介绍患者男38岁,因＂右眼义眼台1期植入术后5年暴露1年＂入院。病程中在外院三次行右眼义眼台暴露结膜切口对位缝合术、羊膜修补术及唇黏膜修补术,结果均失败。体检：右眼睑无红肿,右眼义眼台暴露约6mm×8mm,周围球结膜轻度充血,表面少量粘性物覆盖,眼台运动基本正常,余未见明显异常。完善各项检查后拟局麻下行义眼台暴露自体中薄皮瓣移植修复术。

简介：目的评价带线羟基磷灰石义眼座(HA)无包裹植入的临床疗效.方法对29例眼球摘除术后患者,采用带线羟基磷灰石义眼座作为眼窝植入物,无包裹直接植入.Ⅰ期植入21例.Ⅱ期植入8例.结果分别随访5-18月,4眼术后出现球结膜裂开,2眼术后轻度上睑下垂,1眼术后五月义眼座中度暴露,均经相应治疗后恢复.其他病例手术效果良好,无植入物脱出及移位,义眼座活动度良好.结论带线羟基磷灰石义眼座直接植入术,具有操作简单、材料易得、并发症少等优点,具有良好的应用前景.

简介：我科收治的患眼无视功能患者25例，保留自体巩膜壳，行羟基磷灰石义眼台植入术，现报告如下。

简介：目的探讨低功率半导体激光治疗羟基磷灰石义眼座暴露的疗效.方法采用JAM-II型多功能半导体激光治疗仪(激光物质为GaA1As,激光波长650nm)对22例不同程度的义眼座暴露患者进行激光照射治疗,并将结果与既往采用药物及手术治疗的20例义眼座暴露患者比较.结果激光组22例全部愈合(100%);药物及手术组中轻、中、重度的愈合率分别为83.3%,63.6%和0.经采用X2检验之四格表精确检验法处理,2组间轻度患者的愈合率在统计学上差异无显著性意义(P=0.545),而2组间中度和重度患者的愈合率在统计学上差异有显著性意义(P＜0.05).结论低功率半导体激光治疗羟基磷灰石义眼座暴露的疗效优于药物及手术方法.可用于预防及治疗羟基磷灰石义眼座暴露.

简介：目的研究异体巩膜覆盖羟基磷灰石义眼台植入术的疗效.方法研究15例因各种原因致眼球功能丧失且影响外观患者,行眼球摘除后异体巩膜覆盖羟基膦灰石义眼台.随访至少3个月.结果13例义眼台术后外观及义眼台活动良好.无感染,暴露,运动障碍,2例患者术后早期结膜裂开,眼台轻度暴露,药物保守治疗眼台未脱出,上皮最终均覆盖眼台,顺利植入义眼片.结论异体巩膜覆盖羟基磷灰石义眼台植入术简便、有效、并发症少,适于临床推广.

简介：AIM:Tocomparetheregularityandaccuracyoflaserinsitukeratomileusis(LASIK)flapscreatedbytheZiemerFEMTOLDV'Classic'(Ziemer'Classic')andZiemerFEMTOLDVCrystalLinefemtosecondlaser(ZiemerCrystalLine).METHODS:Fourier-domainopticalcoherencetomography(RTVueOCT)wasusedtomeasurethemorphologyof200LASIKflapsof100consecutivepatientscreatedwiththeZiemerClassic(100flaps)ortheZiemerCrystalLine(100flaps)atoneweekpostoperatively.Flapthicknesswasevaluatedat36specifiedmeasurementpointsoneachflap.Forallprocedureswithbothlasers,thenominalflapthicknesswas110μm.RESULTS:ThemeanflapthicknessoftheZiemerCrystalLinegroup(102.49±2.68μm)wasthinnerthanthatoftheZiemerClassicgroup(107.65±5.09μm)(P<0.01).Averagethicknessofallflapswasuniformwithin4μmatallmeasurementpoints.TheflapsintheZiemerCrystalLinegroupweremoreregularthanthoseintheZiemerClassicgroupwhenmeasuredfromthecentertotheperiphery.Themaximumdeviationfromthenominal110μmof36measurementswas8μmintheZiemerClassicgroup,whileintheZiemerCrystalLinegroupitwas9μm.Withinthe3600measurementsonthe100eyes,differencesgreaterthan20μmwereobserved0.14%intheZiemerClassicgroup,and0.04%intheZiemerCrystalLinegroup.CONCLUSION:TheflapscreatedwiththeZiemerFEMTOLDVCrystalLinefemtosecondlaseraremoreuniformandthinnerthanthosecreatedbytheZiemerFEMTOLDVClassicfemtosecondlaser.

简介：AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra